Adagene, Inc. ( (ADAG) ) has released its Q4 earnings. Here is a breakdown of the information Adagene, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, leveraging its proprietary SAFEbody technology to enhance safety and efficacy. In its 2024 financial report, Adagene highlighted significant progress in its clinical programs, particularly the ADG126 in combination with pembrolizumab, which showed a 33% overall response rate in a Phase 2 trial for colorectal cancer. The company also emphasized its strategic collaborations with major pharmaceutical companies like Exelixis, Sanofi, and Roche to advance its pipeline. Financially, Adagene reported a net loss of $33.4 million for 2024, with a cash balance of $85.2 million expected to support operations until late 2026. Looking ahead, Adagene plans to expand its clinical trials and pursue additional strategic partnerships to further its innovative cancer therapies.